行情

VTVT

VTVT

VTV THERAPEUTICS
NASDAQ

实时行情|Nasdaq Last Sale

2.330
-0.200
-7.91%
盘后: 2.360 +0.03 +1.29% 18:46 01/24 EST
开盘
2.590
昨收
2.530
最高
2.590
最低
2.210
成交量
40.68万
成交额
--
52周最高
3.400
52周最低
1.230
市值
1.40亿
市盈率(TTM)
-3.9385
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VTVT 新闻

  • 蛋壳公寓将为武汉医护人员提供专属免费住房
  • 新浪科技.35分钟前
  • 亚澳美欧11国超30例确诊感染 多国计划从武汉撤侨
  • 界面.40分钟前
  • 红杉中国致信成员企业:坚定信心、砥砺前行
  • 新浪财经.2小时前
  • 波音777X完成首飞:明年起开始交付 未来世界最大客机
  • IT之家.3小时前

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

VTVT 简况

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
展开

Webull提供vTv Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。